Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Osteoporosis International
Published in: Osteoporosis International 9/2016

Open Access 01-09-2016 | Original Article

Association between teriparatide treatment persistence and adherence, and fracture incidence in Taiwan: analysis using the National Health Insurance Research Database

Authors: D.-C. Chan, C. H.-C. Chang, L.-C. Lim, A. J. M. Brnabic, J.-Y. Tsauo, R. Burge, F.-Y. Hsiao, L. Jin, S. Gürbüz, R.-S. Yang

Published in: Osteoporosis International | Issue 9/2016

Login to get access

Abstract

Summary

Medication persistence and adherence are critical for osteoporosis outcomes. Using the Taiwan National Health Insurance Research Database, we found that persistence and adherence to teriparatide were low in Taiwanese patients with osteoporosis and that greater persistence and adherence were associated with a lower incidence of hip and other nonvertebral fractures.

Introduction

The purpose of this study was to determine the persistence and adherence to teriparatide treatment in Taiwanese patients with osteoporosis, and to examine the association between persistence and adherence to teriparatide with fracture risks.

Methods

Medical and pharmacy claims for 4,692 patients with vertebral or hip fractures and teriparatide prescriptions between 2005 and 2008 were identified (Taiwan National Health Insurance Research Database). Persistence was the time from the start of treatment to the first 90-day gap between two teriparatide prescriptions. Adherence was the number of teriparatide pens (each pen is used over 1 month) prescribed over 24 months. Association of persistence and adherence to teriparatide with fracture incidence was assessed using adjusted Cox proportional hazards models.

Results

The proportion of patients persisting with teriparatide for >6 months and >12 months was 44.6 and 24.9 %, respectively. Over 24 months, 53.6 % of patients were adherent for >6 months and 33.9 % were adherent for >12 months. Patients persisting for >12 months had a significantly lower incidence of hip (adjusted hazard ratio [HR], 0.61 [95 % confidence interval (CI), 0.40–0.93], P = 0.0229) and nonvertebral fracture (HR, 0.79 [95 % CI, 0.63–0.99], P = 0.0462) compared with those who persisted for ≤12 months. Patients adherent for >12 months had a lower incidence of hip (HR, 0.66 [95 % CI, 0.46–0.96], P = 0.0286) and nonvertebral fracture (HR, 0.81 [95 % CI, 0.66–0.99], P = 0.0377) compared with those adherent for ≤12 months.

Conclusions

Persistence and adherence to teriparatide over 24 months were low in Taiwanese patients with osteoporosis; greater adherence and persistence were associated with a lower incidence of nonvertebral fractures.
Literature
1.
2.
Inderjeeth CA, Chan K, Kwan K, Lai M (2012) Time to onset of efficacy in fracture reduction with current anti-osteoporosis treatments. J Bone Miner Metab 30:493–503CrossRefPubMed
3.
Johnell O, Kanis JA (2006) An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int 17:1726–1733CrossRefPubMed
4.
Chan DC, Lee YS, Wu YJ, Tsou HH, Chen CT, Hwang JS, Tsai KS, Yang RS (2013) A 12-year ecological study of hip fracture rates among older Taiwanese adults. Calcif Tissue Int 93:397–404CrossRefPubMed
5.
Wang CB, Lin CF, Liang WM, Cheng CF, Chang YJ, Wu HC, Wu TN, Leu TH (2013) Excess mortality after hip fracture among the elderly in Taiwan: a nationwide population-based cohort study. Bone 56:147–153CrossRefPubMed
6.
Kanis JA, Oden A, McCloskey EV, Johansson H, Wahl DA, Cooper C (2012) A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int 23:2239–2256CrossRefPubMedPubMedCentral
7.
Chie WC, Yang RS, Liu JP, Tsai KS (2004) High incidence rate of hip fracture in Taiwan: estimated from a nationwide health insurance database. Osteoporos Int 15:998–1002CrossRefPubMed
8.
Papapoulos SE (2015) Anabolic bone therapies in 2014: new bone-forming treatments for osteoporosis. Nat Rev Endocrinol 11:69–70CrossRefPubMed
9.
Bernabei R, Martone AM, Ortolani E, Landi F, Marzetti E (2014) Screening, diagnosis and treatment of osteoporosis: a brief review. Clin Cases Miner Bone Metab 11:201–207PubMedPubMedCentral
10.
Russell RG, Watts NB, Ebetino FH, Rogers MJ (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19:733–759CrossRefPubMed
11.
Neer RM, Arnaud CD, Zanchetta JR et al (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441CrossRefPubMed
12.
Hodsman AB, Bauer DC, Dempster DW et al (2005) Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr Rev 26:688–703CrossRefPubMed
13.
Krueger KP, Berger BA, Felkey B (2005) Medication adherence and persistence: a comprehensive review. Adv Ther 22:313–356CrossRefPubMed
14.
Modi A, Siris ES, Tang J, Sen S (2015) Cost and consequences of noncompliance with osteoporosis treatment among women initiating therapy. Curr Med Res Opin 31:757–765CrossRefPubMed
15.
Siris ES, Selby PL, Saag KG, Borgstrom F, Herings RM, Silverman SL (2009) Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 122:S3–S13CrossRefPubMed
16.
Briesacher BA, Andrade SE, Yood RA, Kahler KH (2007) Consequences of poor compliance with bisphosphonates. Bone 41:882–887CrossRefPubMed
17.
Penning-van Beest FJ, Erkens JA, Olson M, Herings RM (2008) Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int 19:511–517CrossRefPubMed
18.
Yu S, Burge RT, Foster SA, Gelwicks S, Meadows ES (2012) The impact of teriparatide adherence and persistence on fracture outcomes. Osteoporos Int 23:1103–1113CrossRefPubMed
19.
Lindsay R, Miller P, Pohl G, Glass EV, Chen P, Krege JH (2009) Relationship between duration of teriparatide therapy and clinical outcomes in postmenopausal women with osteoporosis. Osteoporos Int 20:943–948CrossRefPubMed
20.
Rajzbaum G, Grados F, Evans D, Liu-Leage S, Petto H, Augendre-Ferrante B (2014) Treatment persistence and changes in fracture risk, back pain, and quality of life amongst patients treated with teriparatide in routine clinical care in France: results from the European Forsteo Observational Study. Joint Bone Spine 81:69–75CrossRefPubMed
21.
Suk KS, Lee HM, Moon SH, Kim HJ, Kim HS, Park JO, Lee BH (2014) At least one cyclic teriparatide administration can be helpful to delay initial onset of a new osteoporotic vertebral compression fracture. Yonsei Med J 55:1576–1583CrossRefPubMedPubMedCentral
22.
Tanaka I, Sato M, Sugihara T, Faries DE, Nojiri S, Graham-Clarke P, Flynn JA, Burge RT (2013) Adherence and persistence with once-daily teriparatide in Japan: a retrospective, prescription database, cohort study. J Osteoporos 2013:Article ID 654218
23.
24.
Chien L-C, Cheng H-M, Chen W-C, Tsai M-C (2010) Pelvic fracture and risk factors for mortality: a population-based study in Taiwan. Eur J Trauma Emerg Surg 36:131–137CrossRefPubMed
25.
Langdahl BL, Rajzbaum G, Jakob F et al (2009) Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS). Calcif Tissue Int 85:484–493CrossRefPubMedPubMedCentral
26.
Curtis JR, Larson JC, Delzell E et al (2011) Placebo adherence, clinical outcomes, and mortality in the women’s health initiative randomized hormone therapy trials. Med Care 49:427–435CrossRefPubMedPubMedCentral
27.
Foster SA, Foley KA, Meadows ES, Johnston JA, Wang SS, Pohl GM, Long SR (2011) Adherence and persistence with teriparatide among patients with commercial, Medicare, and Medicaid insurance. Osteoporos Int 22:551–557CrossRefPubMed
28.
Nogues X, Luz Rentero M, Rodriguez AL (2014) Use of an educational support program to assist patients receiving injectable osteoporosis treatment: experience with teriparatide. Curr Med Res Opin 30:287–296CrossRefPubMed
29.
Briot K, Ravaud P, Dargent-Molina P, Zylberman M, Liu-Leage S, Roux C (2009) Persistence with teriparatide in postmenopausal osteoporosis; impact of a patient education and follow-up program: the French experience. Osteoporos Int 20:625–630CrossRefPubMed
30.
McLellan AR, Gallacher SJ, Fraser M, McQuillian C (2003) The fracture liaison service: success of a program for the evaluation and management of patients with osteoporotic fracture. Osteoporos Int 14:1028–1034CrossRefPubMed
31.
Boudou L, Gerbay B, Chopin F, Ollagnier E, Collet P, Thomas T (2011) Management of osteoporosis in fracture liaison service associated with long-term adherence to treatment. Osteoporos Int 22:2099–2106CrossRefPubMed
32.
Lin TC, Yang CY, Yang YH, Lin SJ (2011) Alendronate adherence and its impact on hip-fracture risk in patients with established osteoporosis in Taiwan. Clin Pharmacol Ther 90:109–116CrossRefPubMed
33.
Chiu CK, Kuo MC, Yu SF, Su BY, Cheng TT (2013) Adherence to osteoporosis regimens among men and analysis of risk factors of poor compliance: a 2-year analytical review. BMC Musculoskelet Disord 14:276CrossRefPubMedPubMedCentral
34.
Soong YK, Tsai KS, Huang HY, Yang RS, Chen JF, Wu PCH, Huang KE (2013) Risk of refracture associated with compliance and persistence with bisphosphonate therapy in Taiwan. Osteoporos Int 24:511–521CrossRefPubMed
35.
Shen S-H, Huang K-C, Tsai Y-H, Yang T-Y, Lee M-S, Ueng S-W, Hsu R-W (2014) Risk analysis for second hip fracture in patients after hip fracture surgery: a nationwide population-based study. J Am Med Dir Assoc 15:725–731CrossRefPubMed
36.
Lee YK, Ha YC, Choi HJ, Jang S, Park C, Lim YT, Shin CS (2013) Bisphosphonate use and subsequent hip fracture in South Korea. Osteoporos Int 24:2887–2892CrossRefPubMed
37.
Chandran M, Tan MZ, Cheen M, Tan SB, Leong M, Lau TC (2013) Secondary prevention of osteoporotic fractures--an “OPTIMAL” model of care from Singapore. Osteoporos Int 24:2809–2817CrossRefPubMed
38.
Pasion EG, Sivananthan SK, Kung AW et al (2007) Comparison of raloxifene and bisphosphonates based on adherence and treatment satisfaction in postmenopausal Asian women. J Bone Miner Metab 25:105–113CrossRefPubMed
39.
Yu SF, Yang TS, Chiu WC, Hsu CY, Chou CL, Su YJ, Lai HM, Chen YC, Chen CJ, Cheng TT (2013) Non-adherence to anti-osteoporotic medications in Taiwan: physician specialty makes a difference. J Bone Miner Metab 31:351–359CrossRefPubMed
40.
41.
Kyvernitakis I, Kostev K, Kurth A, Albert US, Hadji P (2014) Differences in persistency with teriparatide in patients with osteoporosis according to gender and health care provider. Osteoporos Int 25:2721–2728CrossRefPubMed
42.
Prince R, Sipos A, Hossain A et al (2005) Sustained nonvertebral fragility fracture risk reduction after discontinuation of teriparatide treatment. J Bone Miner Res 20:1507–1513CrossRefPubMed
43.
Black DM, Bilezikian JP, Ensrud KE et al (2005) One year of alendronate after one year of parathyroid hormone (1–84) for osteoporosis. N Engl J Med 353:555–565CrossRefPubMed
44.
Chen P, Miller PD, Recker R, Resch H, Rana A, Pavo I, Sipos AA (2007) Increases in BMD correlate with improvements in bone microarchitecture with teriparatide treatment in postmenopausal women with osteoporosis. J Bone Miner Res 22:1173–1180CrossRefPubMed
Metadata
Title
Association between teriparatide treatment persistence and adherence, and fracture incidence in Taiwan: analysis using the National Health Insurance Research Database
Authors
D.-C. Chan
C. H.-C. Chang
L.-C. Lim
A. J. M. Brnabic
J.-Y. Tsauo
R. Burge
F.-Y. Hsiao
L. Jin
S. Gürbüz
R.-S. Yang
Publication date
01-09-2016
Publisher
Springer London
Published in
Osteoporosis International / Issue 9/2016
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-016-3611-x

Other articles of this Issue 9/2016

Osteoporosis International 9/2016 Go to the issue

Original Article

Cortical bone laminar analysis reveals increased midcortical and periosteal porosity in type 2 diabetic postmenopausal women with history of fragility fractures compared to fracture-free diabetics

Erratum

Erratum to: The aetiology of rickets-like lower limb deformities in Malawian children

Editorial

The use of finite element analysis to estimate the changing strength of bone following treatment for osteoporosis

Original Article

Balloon kyphoplasty versus percutaneous vertebroplasty for treatment of osteoporotic vertebral compression fractures (OVCFs)

Erratum

Erratum to: A retrospective analysis of nonresponse to daily teriparatide treatment

Review

Risk of hip fracture following stroke, a meta-analysis of 13 cohort studies